Patient demographics with disease, type, and duration of prior bisphosphonate intake, histology, and location/region of BONJ
| Patient | Sex | Age (yr) | Disease | Bisphosphonate | Duration of Treatment | Histology | Region |
|---|---|---|---|---|---|---|---|
| 1 | F | 56 | Metastases, breast Ca | Zoledronic acid (Zometa) | 54 mo | ON/OM | 23–28 |
| 2 | F | 85 | MM | Zoledronic acid (Zometa) | 48 mo | ON/OM | 44–46 |
| 3 | F | 64 | MM | Zoledronic acid (Zometa) | 48 mo | ON | 34–37 |
| 4 | F | 60 | Metastases, breast Ca | Zoledronic acid (Zometa) | 48 mo | ON | 35–36 and 45 |
| 5 | F | 59 | Metastases, mamma Ca | Zoledronic acid (Zometa) | 36 mo | ON | 14–17 |
| 6 | F | 53 | Osteoporosis | Ibandronic acid (Bondronat oral) | 12 mo | ON | 45–47 |
| 7 | F | 86 | Osteoporosis | Ibandronic acid (Bondronat oral) | Not available | ON | 45–47 |
| 8 | F | 79 | Metastases, breast Ca | Zoledronic acid (Zometa) | 7 mo | ON | 11–15 |
| 9 | M | 66 | MM | Zoledronic acid (Zometa) | 60 mo | ON | 14–15 |
| 10 | F | 88 | Metastases, breast Ca | Zoledronic acid (Zometa) | Not available | Not operated | 17–18 |
Note:—ON indicates osteonecrosis; OM, osteomyelitis; MM, multiple myeloma; Ca, cancer; Mamma, mammary.